Resource id #3DrugId:1d00000142resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   


Drug ID: 1d00000142

Drug Name: Azacitidine

Generic Names: Vidaza

Category: Chemotherapy

Legal Status: Non Opioid Prescription only drug

OTC: No

Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: First Treatment Cycle: The recommended starting dose is 75 mg/m2, daily for 7 days.

Subsequent Treatment Cycles: Cycles should be repeated every 4 weeks. The dose may be increased to 100 mg/m2.

Recommended In: This medication is an antineoplastic agent, prescribed for blood cancer. It slows or stops the growth of cancer cells by killing abnormal cells in the bone marrow.

Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein or large muscle.

Storage: Store unreconstituted vials at room temperature (25ºC).

Dosage Forms: Reconstituted vials for Intravenous and Intramuscular injection

Side Effects: Most Common - Nausea, anemia, decrease in blood cells, vomiting, pyrexia, diarrhea, injection site redness, constipation and skin discoloration.

Blood- Anemia.

Gastrointestinal - Abdominal tenderness, constipation, diarrhea, gum bleeding, loose stools, bleeding of mouth, nausea, vomiting and mouth ulcer.

General - Chest pain, injection site bruising, redness, pain, pigmentation, itching, swelling; lethargy, uneasiness and fever.

Infections - Pneumonia and upper respiratory tract infection.

Metabolic - Loss of appetite.

Musculoskeletal - Joint pain, chest wall pain and muscle pain.

Central Nervous system - Dizziness, headache, anxiety and sleeplessness.

Respiratory - Difficulty in breathing.

Skin - Dry skin, discoloration, redness, rash, scar and hives.

Heart - Blood clot, low blood pressure, and red spots.

Miscellaneous- Tumor lysis syndrome, injection site necrosis and Sweet’s syndrome.

In Case of Overdose: In the event of overdosage, the patient should be monitored with appropriate blood counts and should receive supportive treatment, as necessary. There is no known specific antidote for Azacitidine overdosage.

Avoid If: Caution should be exercised in patients with history of kidney or liver problems, any allergy, who are taking other medication, elderly, children, during pregnancy and breastfeeding.

It may cause dizziness, fainting, or lightheadedness, do not drive a car or operate machinery and get up slowly from bed while taking this medication.

It may reduce platelet counts; avoid injury or bruising.

Monitor liver, kidney functions, and blood cell counts regularly while taking this medication.

Avoid contact with people who have infections.

Contraindicated in patients with advanced liver cancer and hypersensitivity.

Drug Interaction: No formal clinical assessments of drug-drug interactions between Azacitidine and other agents have been conducted.



Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main